The agreement to acquire the operations of Ireland-based Actavis, a global, integrated speciality pharmaceutical company, was announced in January 2014.
According to a communique to stock exchanges, Aurobindo has acquired personnel, commercial infrastructure, products, marketing authorisations and dossier licence rights in seven European countries. Actavis and Aurobindo have also entered into a long-term commercial and supply arrangement.
Also Read
Aurobindo now intends to combine the strength of both enterprises in these markets and to identify and maximise all opportunities to improve performance.
Senior vice president of the company’s European operations, Muralidharan, said the acquisition would make Aurobindo one of the leading Indian pharmaceutical companies in Europe.
It “will enable Aurobindo to achieve critical mass in western Europe with a top 10 position in several key markets,” he added.